My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Encorafenib (LGX818)
    Encorafenib (LGX818)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1014
    CAS #: 1269440-17-6Purity ≥98%

    Description: Encorafenib (formerly LGX818; LGX-818; trade name Braftovi), an approved anticancer drug, is a highly potent, and orally bioavailable B-RAFV600E inhibitor with potential antineoplastic activity. It inhibits B-Raf V600E with an IC50 of 4 nM. It has little effect against wild-type BRAF. As of June 2018, Encorafenib was approved by FDA to treat unresectable or metastatic melanoma. Encorafenib has selective anti-proliferative and apoptotic activity on cells expressing BRAFV600E. It shows no significant activity against a panel of 100 kinases and no suppression of cell growth with more than 400 cell lines expressing BRAFV600E. In human melanoma xenograft models, oral administration of Encorafenib shows strong decrease in phospho-MEK and induces tumor regression. Raf kinase is a serine/threonine enzyme in the RAFMAPK/ERK signaling pathway. By inhibiting the activation of the RAF/MAPK/ERK signaling pathway, encorafenib may result in a decrease in the proliferation of tumor cells. 

    References: [1] Cancer Res, 2012, 72(8 Supplement): 3790[2] J Hematol Oncol. 2013 Apr 25;6:30

    Related CAS#: 1269440-29-0 (R-isomer)   

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)540.01
    FormulaC22H27ClFN7O4S
    CAS No.1269440-17-6; 1269440-29-0 (R-isomer of LGX-818)  
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (185.2 mM)
    Water: <1 mg/mL
    Ethanol: 100 mg/mL (185.2 mM)
    SMILES CodeO=C(OC)N[[email protected]@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1
    SynonymsLGX-818; Encorafenib; LGX818; LGX 818


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Encorafenib (formerly known as LGX818) is a new-generation, highly potent, and orally bioavailable B-RAF(V600E) inhibitor with IC50 of 4 nM. It has little effect against wild-type BRAF. Encorafenib has selective anti-proliferative and apoptotic activity on cells expressing BRAFV600E. It shows no significant activity against a panel of 100 kinases and no suppression of cell growth with more than 400 cell lines expressing BRAFV600E. In human melanoma xenograft models, oral administration of Encorafenib shows strong decrease in phospho-MEK and induces tumor regression. Raf kinase is a serine/threonine enzyme in the RAFMAPK/ERK signaling pathway. By inhibiting the activation of the RAF/MAPK/ERK signaling pathway, encorafenib may result in a decrease in proliferation of tumor cells.  In the A375 (BRAFV600E) human melanoma cell line LGX818 suppresses phospho-ERK (EC50 = 3 nM) leading to potent inhibition of proliferation (EC50 = 4 nM). No significant activity is observed against a panel of 100 kinases (IC50 > 900 nM) and LGX818 does not inhibit proliferation of > 400 cell lines expressing wild-type BRAF. Contributing to the high potency of LGX818 is the extremely slow off-rate from BRAFV600E which is not observed with other RAF inhibitors. In biochemical assays the dissociation half-life is >24 hours which translated into sustained target inhibition in cells following drug wash-out.


    Kinase Assay: The Raf kinase activity reaction is started by the addition of 10 μL per well of 2×ATP diluted in assay buffer. After 3 hours (bRaf(V600E)) or 1 hour (c-Raf), the reactions are stopped with the addition of 10 μL of stop reagent (60 mM EDTA). Phosphorylated product is measured using a rabbit anti-p-MEK antibody and the Alpha Screen IgG (ProteinA) detection Kit, by the addition of 30 μL to the well of a mixture of the antibody (1:2000 dilution) and detection beads (1:2000 dilution of both beads) in bead buffer (50 mM Tris, pH 7.5, 0.01% Tween20). The additions are carried out under dark conditions to protect the detection beads from light. A lid is placed on top of the plate and incubated for 1 hour at room temperature, then the luminescence is read on a PerkinElmer Envision instrument. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software. 


    Cell Assay: A375 is a melanoma cell line that harbors the B-Raf V600E mutation. A375-luc cells engineered to express luciferase is plated to 384-well white clear bottom plates as 1,500 cells/50 μL/well in DMEM containing 10% FBS. Test compounds, dissolved in 100% DMSO at appropriate concentrations, are transferred to the cells by a robotic Pin Tool (100 mL). The cells are incubated for 2 days at 25°C, then 25 μL of BrightGloTM is added to each well and the plates are read by luminescence. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software. wild type and V600E B-Raf.

    In VivoLGX818 treatment at oral doses as low as 6 mg/kg resulted in strong (75%) and sustained (>24 hours) decrease in phospho-MEK, even following clearance of drug from circulation in single dose PK/PD studies in human melanoma xenograft models (BRAFV600E). LGX818 induces tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1 mg/kg. Consistent with the in vitro data, LGX818 is inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid, with good tolerability and linear increase in exposure. Efficacy is also achieved in a more disease-relevant spontaneous metastatic melanoma and a model of melanoma brain metastasis. LGX818 is a potent and selective RAF kinase inhibitor with unique biochemical properties that contribute to an excellent pharmacological profile.
    Animal modelRats
    Formulation & Dosage6 mg/kg; oral
    References[1] Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790[2] J Hematol Oncol. 2013 Apr 25;6:30


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Encorafenib (LGX818)

    Fig. 1. LGX818 suppresses the ERK/MAPK pathway, inhibits proliferation and induces cell cycle arrest in BRAFV600E melanoma cells.  2016 Jan 28;370(2):332-44.

    Encorafenib (LGX818)

    Fig. 2. LGX818 downregulates CyclinD1 dependent of DYRK1B, but not GSK3β.  2016 Jan 28;370(2):332-44.

    Encorafenib (LGX818)

    Fig. 3. Apoptosis is not involved in LGX818-mediated melanoma cell growth inhibition.  2016 Jan 28;370(2):332-44.

    Encorafenib (LGX818)

    Fig. 4. LGX818 induces senescence in BRAFV600E melanoma cells. 2016 Jan 28;370(2):332-44.

    Encorafenib (LGX818)

    Fig. 5. LGX818 enhances autophagic flux and induces autophagy via inhibition of the mTOR pathway in BRAFV600E melanoma cells.  2016 Jan 28;370(2):332-44.

    Encorafenib (LGX818)

    Fig. 6. Autophagy is involved in LGX818-induced senescence in BRAFV600E melanoma cells.   2016 Jan 28;370(2):332-44.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?